Roivant Sciences reported first-quarter fiscal 2026 R&D expenses of approximately $200 million and a GAAP G&A expense of $166 million, while its cash position stood at just under $4 billion before receiving a $772 million settlement payment from Moderna. The company received the initial $950 million upfront payment, with approximately $770 million allocated to Genevant and the remainder to Arbutus. Roivant also repurchased approximately $200 million in shares during the quarter at an average price in the high $20s. The company initiated a Phase 3 study in cutaneous sarcoidosis for brepocitinib ahead of schedule and is on track for a potential launch of brepocitinib in dermatomyositis by the end of September.
Roivant Sciences LtdRoivant received $772 million from Moderna settlement and repurchased shares.
Moderna IncModerna paid a $950 million settlement to Roivant, reducing its cash.
Genevant received approximately $770 million from the Moderna settlement.
